Idiopathic Pulmonary Fibrosis (IPF)

Respiratory
6
Pipeline Programs
6
Companies
16
Clinical Trials
2 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
2
0
4
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

6 companies ranked by most advanced pipeline stage

Avalyn Pharmaceuticals
1 program
1
AP02Phase 21 trial
Active Trials
NCT07194382Not Yet RecruitingEst. Jun 2027
Vicore Pharma
Vicore PharmaSweden - Stockholm
1 program
1
BuloxibutidPhase 21 trial
Active Trials
NCT06588686Recruiting360Est. Jun 2027
Rein Therapeutics
1 program
1
LTI-03Phase 21 trial
Active Trials
NCT06968845RecruitingEst. Dec 2027
Liminal BioSciences
1 program
1
PBI4050Phase 21 trial
Active Trials
NCT02538536CompletedEst. Jan 2017
Bristol Myers Squibb
1 program
1
BMS-986278Phase 15 trials
Active Trials
NCT07441408Not Yet Recruiting2,277Est. Mar 2030
NCT06715683Completed48Est. Mar 2025
NCT06723535Completed27Est. Sep 2025
+2 more trials
Contineum Therapeutics
1 program
1
PIPE-791Phase 11 trial
Active Trials
NCT06683612Completed16Est. Jun 2025

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
Bristol Myers SquibbBMS-986278
Rein TherapeuticsLTI-03
Avalyn PharmaceuticalsAP02
Vicore PharmaBuloxibutid
Liminal BioSciencesPBI4050
Bristol Myers SquibbBMS-986278
Contineum TherapeuticsPIPE-791
Bristol Myers SquibbBMS-986278
Bristol Myers SquibbBMS-986278
Bristol Myers SquibbBMS-986278
Bristol Myers SquibbBMS-986278
Bristol Myers SquibbBMS-986278
Bristol Myers SquibbBMS-986278
Bristol Myers SquibbBMS-986278
Bristol Myers SquibbBMS-986278

Showing 15 of 16 trials with date data

Clinical Trials (16)

Total enrollment: 3,014 patients across 16 trials

NCT07441408Bristol Myers SquibbBMS-986278

Long-term Extension Study to Evaluate Safety and Tolerability of Admilparant in Participants With Pulmonary Fibrosis

Start: Dec 2026Est. completion: Mar 20302,277 patients
Phase 3Not Yet Recruiting
NCT06968845Rein TherapeuticsLTI-03

A Phase 2 Study of LTI-03 in Patients With Idiopathic Pulmonary Fibrosis

Start: Feb 2026Est. completion: Dec 2027
Phase 2Recruiting
NCT07194382Avalyn PharmaceuticalsAP02

AURA-IPF: A Randomized Phase 2 Study to Evaluate the Safety and Efficacy of AP02 (Nintedanib Solution) in IPF

Start: Jan 2026Est. completion: Jun 2027
Phase 2Not Yet Recruiting
NCT06588686Vicore PharmaBuloxibutid

A Trial to Evaluate Efficacy and Safety of Buloxibutid in People With Idiopathic Pulmonary Fibrosis.

Start: Dec 2024Est. completion: Jun 2027360 patients
Phase 2Recruiting
NCT02538536Liminal BioSciencesPBI4050

A Phase 2 Study to Evaluate the Safety and Tolerability of PBI-4050 in Patients With Idiopathic Pulmonary Fibrosis (IPF)

Start: Jul 2015Est. completion: Jan 2017
Phase 2Completed
NCT06715683Bristol Myers SquibbBMS-986278

A Study to Evaluate Comparative Bioavailability of BMS-986278 in Healthy Participants

Start: Dec 2024Est. completion: Mar 202548 patients
Phase 1Completed
NCT06683612Contineum TherapeuticsPIPE-791

PET Study of PIPE-791 in Healthy Volunteers and Volunteers With PrMS and IPF

Start: Dec 2024Est. completion: Jun 202516 patients
Phase 1Completed
NCT06723535Bristol Myers SquibbBMS-986278

A Study to Evaluate BMS-986278 in Participants With Normal Renal Function, Severe Renal Impairment, or End-Stage Renal Disease on Intermittent Hemodialysis

Start: Dec 2024Est. completion: Sep 202527 patients
Phase 1Completed
NCT06568458Bristol Myers SquibbBMS-986278

A Study to Assess the Extent of Drug Interaction Between BMS-986278 and Nintedanib, the Relative Bioavailability of BMS-986278 in Tablet and the Effect That Food Has on BMS-986278 in Tablet Formulations in Healthy Participants

Start: Sep 2024Est. completion: Feb 202571 patients
Phase 1Completed
NCT06425198Bristol Myers SquibbBMS-986278

Study to Assess Drug Levels and Safety of BMS-986278 in Healthy Participants and Participants With Different Degrees of Hepatic Impairment

Start: Jun 2024Est. completion: Dec 202437 patients
Phase 1Completed
NCT05985590Bristol Myers SquibbBMS-986278

A Study to Investigate the Effects of BMS-986278 on Drospirenone and Ethinyl Estradiol Drug Levels in Healthy Female Participants

Start: Aug 2023Est. completion: Dec 202337 patients
Phase 1Completed
NCT05932303Bristol Myers SquibbBMS-986278

A Study to Assess the Effect of Multiple Doses of Itraconazole, Gemfibrozil, or Carbamazepine on BMS-986278 in Healthy Participants

Start: Jul 2023Est. completion: Oct 202347 patients
Phase 1Completed
NCT04567667Bristol Myers SquibbBMS-986278

Study to Assess the Way the Body Absorbs, Distributes, Breaks Down and Eliminates Radioactive BMS-986278 in Healthy Male Participants

Start: Oct 2020Est. completion: Apr 20219 patients
Phase 1Completed
NCT04468815Bristol Myers SquibbBMS-986278

A Study to Assess the Levels in Blood Plasma of BMS-986278 in Healthy Participants Following Administration of Tablets, With or Without Food, and in the Presence of an Antacid (Esomeprazole)

Start: Jul 2020Est. completion: Oct 202024 patients
Phase 1Completed
NCT03981094Bristol Myers SquibbBMS-986278

A Study of the Pharmacokinetic Interaction Between Pirfenidone and BMS-986278 in Healthy Participants

Start: May 2019Est. completion: Jul 201922 patients
Phase 1Completed
NCT03712540Bristol Myers SquibbBMS-986278

An Investigational Study of Experimental Medication BMS-986278 Given With the Antibiotic Rifampin in Healthy Participants

Start: Sep 2018Est. completion: Nov 201839 patients
Phase 1Completed

Related Jobs in Respiratory

Ausbildung zum Pharmakanten (m/w/d)

Ferring Pharmaceuticals
Kiel, Germany
20h ago

Global Senior Medical Director – Respiratory Pipeline Medical Lead

Pfizer
United States - New York - New York City
Yesterday
$275K - $458K/yr

Praktikant (m/w/d) Marketing Onkologie

Amgen
Germany - Munich
Yesterday

Sr Product Manager, Monarch (1 of 2)

Johnson & Johnson
Santa Clara, California, United States of America
Yesterday
$142K - $245K/yr

Laboratory Assistant (m/w/d)

Ferring Pharmaceuticals
Kiel, Germany
Yesterday

Director Quality Control (m/w/d)

Ferring Pharmaceuticals
Kiel, Germany
Yesterday

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

2 actively recruiting trials targeting 3,014 patients
6 companies competing in this space

Related Indications

Asthma(378)Pulmonary Disease, Chronic Obstructive(263)Chronic Obstructive Pulmonary Disease(123)Idiopathic Pulmonary Fibrosis(90)COPD(74)Chronic Obstructive Pulmonary Disease (COPD)(38)Pulmonary Embolism(27)Respiratory Syncytial Virus Infections(26)Severe Asthma(21)Lung Diseases, Interstitial(19)